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Abstract
Background: Research suggests that food intolerance may be a precipitating factor for migraine like headaches.
Aim: To evaluate the effectiveness of the ELISA (Enzyme Linked Immuno-Sorbent Assay) Test and subsequent
dietary elimination advice for the prevention of migraine like headaches.
Design: Randomised controlled trial.
Setting: Community based volunteers in the UK.
Participants: Volunteers who met the inclusion criteria for migraine like headaches and had one or more food
intolerance were included in the study. Participants received either a true diet (n = 84) or a sham diet (n = 83)
sheet. Participants were advised to remove the intolerant foods from their diet for 12 weeks.
Main outcome measures: Number of headache days over a 12 week period (item A MIDAS questionnaire). Other
measures includes the total MIDAS score and total HIT-6 score.
Results: The results indicated a small decrease in the number of migraine like headaches over 12 weeks, although
this difference was not statistically significant (IRR 1.15 95% CI 0.94 to 1.41, p = 0.18). At the 4 week assessment,
use of the ELISA test with subsequent diet elimination advice significantly reduced the number of migraine like
headaches (IRR 1.23 95%CI 1.01 to 1.50, p = 0.04). The disability and impact on daily life of migraines were not
significantly different between the true and sham diet groups.
Conclusions: Use of the ELISA test with subsequent diet elimination advice did not reduce the disability or impact
on daily life of migraine like headaches or the number of migraine like headaches at 12 weeks but it did
significantly reduce the number of migraine like headaches at 4 weeks.
Trial registration number: ISRCTN: ISRTCN89559672
Keywords: headache, diet, food elimination, randomised controlled trial
Introduction
Migraine is a condition associated with a severe one
sided headache [1,2], which may be accompanied by
nausea [3], vomiting, diarrhoea, blurry vision and photo-
phobia [4]. Approximately 6-7% of men and up to 20%
of women report experiencing migraine headaches [1].
It is considered by some that severe migraine can be as
disabling as quadriplegia and is the cause of many Gen-
eral Practitioner (GP) consultations [5]. As well as hav-
ing an impact on quality of life, migraine has a
significant economic impact, with migraine sufferers
requiring 4-6 bed rest days per year [6,7].
The aetiology of migraine attacks is not completely
understood [8]. However, a number of precipitating fac-
tors have been identified in the literature including
change in stress levels, excessive afferent stimuli, altered
sleep patterns, weather change, and food [5,8].
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tific research since the early 1900s. Early studies found
that elimination of specific foods from a person’sd i e t
c o u l dp r e v e n tt h eo n s e to fam i g r a i n eo rr e d u c et h e
number of symptoms experienced [9,10]. More recent
research suggests that food hypersensitivity (intolerance)
may be a precipitating factor for migraine attacks [11]
and about 25% of migraine patients report that their
symptoms can be initiated by certain foods [12]. How-
ever, the role of food in migraine is still controversial.
Unfortunately, the quality of the research (e.g. study
design and sample size) generally in this field has not
been very high [13-16]. Currently, the best accepted
method for diagnosing and confirming food hypersensi-
tivity is empirical, by elimination diet and challenge
[17]. This method is laborious, and it is difficult to test
all the combinations of food types that may be causing
the problems. Previous studies which have looked at
testing for food intolerance have focused on the pre-
sence of IgE antibodies, the “immediate response”
[18,19]. An alternative approach would be to measure
food specific IgG antibodies which characteristically
e x h i b i t sas l o w e rr e s p o n s e[ 1 8 , 2 0 ] .T h ep r e s e n c eo f
food-specific IgGs may indicate a potential sensitivity to
that particular food, previous studies have shown a rela-
tionship between IgG and food hypersensitivity [21-23].
Food specific antibody levels can be measured through
the use of an Enzyme Linked Immuno-Sorbent Assay
(ELISA), in the form of a simple blood test. The use of
this test as the basis of food elimination diets is contro-
versial with little evidence to support its use for
migraines. A small cross over trial (n = 30) participants
using ELISA testing has recently been reported, which
demonstrated a significantly reduced frequency of head-
ache days among a group of patients recruited from a
h e a d a c h ec l i n i c( 2 7 ) .I nt h i ss t u d yw eu n d e r t o o ka
further RCT of ELISA testing in a real life setting.
Methods
The study was a single blind, two arm randomised con-
trolled trial in which participants were randomised to
either a “true” diet or “sham” diet control group. Partici-
pants were allocated to one of the two diet sheets based
on a randomisation schedule developed using a random
computer number generator by an independent data
manager. Simple randomisation was used with no
restrictions (e.g. blocking and/or stratification) placed
on the randomisation. All participants and staff at
YorkTest Laboratories were blinded to group assign-
ment for the duration of the study.
Identifying participants
Participants were recruited through advertisements and
a press release. An advert for the trial was placed in the
Migraine Action Association newsletter and on the Uni-
versity of York’s webpage. Additionally there was a press
release to the local media. Participants who expressed
an interest in taking part in the study between March
and June 2008 were sent further details about the study,
a baseline questionnaire and a consent form. Because
the participants were recruited through advertisement
and through the completion of a postal questionnaire
we could not be certain that all of them had a clinical
diagnosis of migraine. Consequently, those recruited to
the study did have self reported headaches that were
‘migraine like’. Whilst most of the participants are likely
to have had migraines it is possible that some did not.
All participants aged 18-65, who had a self-reported
diagnosis of migraine for at least 12 months, had no evi-
dence of any other significant co-existing pathology and
experienced 2 or more migraine like attacks (or 4 or
more headache days) in the previous 4 week period
were eligible for the screening phase. We wanted to
recruit participants who were having regular migraines
or migraine like headaches in order to maximise the
power of the study.
At screening, potentially eligible participants were
sent a pin prick test kit, supplied, at no cost, by
YorkTest Laboratories Ltd (York, UK), with only a
numerical identifier. Participants were asked to follow
the instructions of the pin prick test in order to supply
a small blood sample. Participants were asked to
return this blood sample directly to YorkTest Labora-
tories. YorkTest Laboratories carried out an ELISA test
to detect the presence of IgG antibodies specific to a
panel of 113 different food antigens (see Table 1). Par-
ticipants who had one or more food intolerances iden-
tified from the ELISA test were eligible for inclusion in
the study. The cut-off used to determine food-specific
IgG antibodies are detected or not was 10 AU (arbi-
trary units) per millilitre (AU/ml) of blood. Most of
the 113 foods were tested individually. There were
some that were tested as mixers (e.g., melon mix
includes watermelon, honeydew and Cantaloupe
melon). Participants were asked to remove all the
foods in that particular mix (if appropriate). The test is
CE marked and test reproducibility meets the require-
ments of the European IVD Directive. Participants who
showed no evidence of food sensitivity in the ELISA
test were excluded from randomisation and were
informed of their true test results.
Treatment and control group interventions
For each participant two diet sheets were generated by
YorkTest Laboratories - a true diet sheet and a sham
diet sheet. The sham diet sheet asked participants to
eliminate the same number of foods to which they
exhibited IgG antibodies but not those particular foods.
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to be eliminated and also for the difficultly of eliminat-
ing foods. YorkTest Laboratories sent the true and sham
diet sheets for each participant to the York Trials Unit,
again with only a number for identification.
Participants were sent the appropriate diet sheet and
were advised to remove foods to which they showed a
positive reaction from their diet for a period of 12
weeks. At the end of this phase of the study, both
groups were asked to reintroduce, in a stepwise fashion,
the foods which they had been asked to eliminate.
Participants were asked to reintroduce one food at a
time on a weekly basis and continue with the food if no
migraine or migraine like headache occurred. Food rein-
troduction occurred over a 4 week period with all elimi-
nated foods (if no migraine or migraine like headache
had occurred) being introduced in the final week. Parti-
cipants were advised to stop consuming any reintro-
duced food if a migraine or migraine like headache
occurred and to continue to reintroduce one of the
other remaining foods. At the end of the follow up per-
iod all participants were told which diet sheet they had
been given. Participants were sent the appropriate diet
sheet to commence diet elimination in September 2008.
Measurements
The baseline questionnaire recorded information about
participants experience with migraine, including: fre-
quency of migraines or migraine like headache in the
previous 4 weeks (number of headache days), symptoms
experienced, migraine medication use, whether they
have previously excluded foods from their diet, and any
consultations with healthcare professionals about their
migraine or migraine like headache. The questionnaire
also included a measure of disability using the MIgraine
Disability Assessment Scale (MIDAS) [24] and impact
on daily life using the Headache Impact Test (HIT-6™)
[25,26]. Baseline questionnaires were sent out to partici-
pants at the beginning of July 2008. Reminders were
sent 3 weeks later if participants had not returned their
original questionnaire. Participants were followed-up at
4 weeks (October 2008) and 12 weeks (December 2008)
after starting their allocated diet with a short question-
naire which included the MIDAS, HIT-6 and an addi-
tional question asking if the participant had consulted
with a GP about their migraine or migraine like head-
ache over the past 4 or 8 weeks depending on the
timing.
The MIDAS questionnaire assesses headache-related
disability. Respondents are asked to answer five ques-
tions, scoring the number of days, in the past 3 months,
that they have had activity limitations due to headaches.
Two additional items (A and B) are also included which
ask about the number of headaches over the past 3
months and how painful the headaches were. The Head-
ache Impact Test (HIT) is a tool to measure the impact
headaches have on a person’s ability to function on the
job, at home, at school and in social situations. Respon-
dents are asked to answer six questions covering aspects
of functioning mostly impacted by headache: pain, role
functioning (the ability to carry out usual activities),
social functioning, energy or fatigue, cognition, and
emotional distress. The responses on each question are
described on a 5-point Likert scale including: never,
rarely, sometimes, very often and always.
Table 1 Foodscan 113 - the foods tested
Dairy Kiwi Duck Spinach
Cows milk Lemon Lamb Lettuce
Egg white Lime Pork Mustard mix
Egg yolk Melon mix Turkey (cabbage,
broccoli,
(honeydew, cauliflower,
Fish watermelon, Nuts brussel sprout)
Crustacean mix cantaloupe) Almonds Onion
(crab, lobster, Olive Brazil nut Pea
prawn, shrimp) Orange Cashew Pepper
Fish mix (cod, Peach Coconut (capsicum)/
paprika
haddock) Pear Hazelnut Potato
Mollusc mix Pineapple Peanut Soya bean
(oyster, mussel, Plum Walnut String bean
scallop) Raspberry
Oily fish mix Strawberry Grains Other
(mackerel,
herring)
Tomato Barley Carob
Plaice/Sole Buckwheat Cocoa bean
Salmon/Trout Herbs/Spices Corn (maize) Coffee
Tuna Chilli pepper Gluten
(gliadin)*
Cola nut
Cinnamon/clove Millet Hops
Fruit Coriander/cumin/
dill
Oat Lentils
Apple Garlic Rice Mushroom
Apricot Mint mix (mint, Rye Sunflower seed
Avocado sage, basil, thyme) Wheat Sesame seed
Banana Mustard seed Tea
Blackberry Nutmeg/
peppercorn
Vegetables Yeast
Blackcurrant Parsley Asparagus
Cherry Vanilla Aubergine
Cranberry Carrot
Cucumber Meats Celery
Grape Beef Haricot bean
Grapefruit Chicken Kidney bean
*A positive (IgG reaction) to gluten is not diagnostic of celiac disease
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the 12 weeks they were in the food elimination phase of
the trial. The diary recorded whether or not they had a
migraine or migraine like headache, the duration of the
migraine or migraine like headache, the treatments they
used and a migraine/headache severity score (0 to 10
where 0 is no pain and 10 is pain as bad as it can be).
Participants in the “true” diet group were also asked to
record their adherence to the diet each day in the diary.
Participants were asked the following question: “Have
you followed the study-related dietary advice today?”.I f
participants answered “yes” to the question 70% of the
time they were categorised as “adhering to the diet most
of the time.”
Sample size
In a population survey of migraine sufferers it was found
that on average patients had 13 migraines or headache
days over a 12 week period (our follow-up period) with
a standard deviation of 11 [24]. We sought a reduction
of 5 headache days. Assuming a standard deviation of
11 this results in a standardised effect size (difference in
means/standard deviation) of 0.45. This reduction of a
0.45 of a standard deviation was similar to that observed
in a recent acupuncture trial for migraine prevention
[2]. To detect this effect size, assuming 80% power, an
independent samples t-test and a 2-sided 5% significance
level we required 78 participants per group, 156 in total.
Allowing for 10% loss to follow up we required a total
of 174 participants (87 per group).
Statistical analysis
The primary outcome measure was the number of head-
ache days over a 12 week period (item A on the MIDAS
questionnaire) which was calculated by summing
responses on the 4 and 12 week questionnaires. A head-
ache day was defined as any 24 hour period in which
the patient reported that they had had a migraine attack
which lasted more than 4 hours. Secondary outcome
measures were the total MIDAS score and total HIT-6
score. The total MIDAS score was calculated by sum-
ming the total number of days from questions 1 to 5
(ignoring A and B). The HIT-6 scores were calculated
by assigning a value of 6 to a response of “Never,” 8t o
“Rarely,” 10 to “Sometimes,” 11 to “Very Often,” and 13
to “Always;” these values were then summed. Scores can
range from 36 (lowest possible score) to 78 (highest pos-
sible score).
All analyses were conducted on an intention to treat
bases, including all randomised patients in the groups
to which they were randomised. Analyses were con-
ducted in SAS (version 9.1) and SPSS (version 15). We
compared the number of migraines in the intervention
and control groups using negative binomial regression
models with adjustments for baseline scores. These
models are used to estimate the number of occur-
rences of an event when the event has Poisson varia-
tion with over-dispersion. We also used a negative
binomial regression model to compare the total
MIDAS scores in the intervention and control groups
with similar adjustments for baseline scores. A linear
regression model was used to compare the total HIT6
scores between the intervention and control groups
after adjustment for baseline scores. Stricter levels of
significance were used (p = 0.01) for secondary out-
comes to compensate for multiple testing. Multiple
imputation was used to account for the missing data.
Five imputations were created using a set of appropri-
ate imputation models constructed using variables that
were predictive of the missing data (e.g. age, baseline
number of headache days) and the group allocation.
Multiple imputation was performed using the mi pro-
cedure in SAS with the assumption that the data were
missing at random.
Results
Recruitment of participantsa n dt h e i rf l o wt h r o u g ht h e
study is illustrated in Figure 1. In summary, between
March 2008 and June 2008, 289 interested participants
contacted York Trials Unit to register their interest in
the study. Of the 289 questionnaires sent out, 245 (85%
of interested participants) returned the questionnaire to
be assessed for eligibility. Seventy eight participants
were not randomised into the study as they did not
meet the inclusion criteria, they withdrew consent, they
did not return a blood sample for testing or they did
not have any food intolerance identified by the ELISA
test. A total of 167 participants (68% of eligible partici-
pants) were randomised, 83 to the sham diet and 84 to
the true diet. At 12 weeks follow-up, 71 of the 83 parti-
cipants in the sham diet group and 67 of the 84 partici-
pants in the true diet group returned their
questionnaires (83% response rate).
Participant characteristics
Table 2 shows the baseline demographic, clinical symp-
toms and contact with healthcare professionals of the
two diet groups. The ELISA tested IgG antibodies speci-
fic to a panel of 113 different food antigens (see Table
1). These different foods were broadly categorized into 9
food groups: grains (e.g. wheat, oat, rye), dairy (e.g. cows
milk, egg white), meats (e.g. pork, lamb), fish (e.g. sal-
mon/trout, tuna), vegetables (e.g. lentils, soya bean, car-
rot), fruits (e.g. blackcurrant, peach, pineapple), nuts (e.
g. cashew, brazil, peanut), herbs/spices (e.g. coriander/
cumin/dill, chilli pepper, garlic) and others (e.g. cola
nut, sunflower seed, tea). The frequency of food groups
excluded from the diet is shown in Table 3. As Table 3
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eliminated across the two groups.
Primary outcome
The primary outcome was the number of headache days
reported over the 12 weeks of diet elimination and was
a v a i l a b l ef o r6 9o ft h es h a ma n d6 9o ft h et r u ed i e t
group (Table 4). The median number of headache days
i nt h es h a md i e tg r o u pw a s2 0( I Q R=1 2t o2 9 )a n di n
the true diet group was 19 (IQR = 8 to 28). There was
no significant difference in the reduction of migraines in
t h et r u ea n ds h a md i e tg r o u p sa t1 2w e e k s( I R R1 . 1 5
95% CI 0.94 to 1.41, p = 0.18). Similar results were
found when multiple imputation was used to account
for the missing data (IRR 1.17 95% CI 0.96 to 1.42, p =
0.11). When the data were analysed for the number of
headache days at 4 weeks there was a significant differ-
ence between the two groups (sham n = 78, median = 8,
Sent baseline 
questionnaire (n = 289) 
Assessed for eligibility (n = 245) 
Randomised (n = 167)  
4 week follow-up (n = 77) 
 
Withdrew consent (n = 1) 
No response (n = 5) 
4 week follow-up (n = 77) 
 
Withdrew consent (n = 2) 
No response (n = 6) 
Sham diet (n = 83)  True diet (n = 84) 
12 week follow-up (n = 67) 
 
Withdrew consent (n = 1) 
No response (n = 14) 
12 week follow-up (n = 71) 
 
Withdrew consent (n = 0) 
No response (n = 11) 
Total excluded (n = 78) 
 
Not meet inclusion criteria (n = 49) 
Withdrew consent (n = 17) 
Not returned blood sample (n = 5) 
No food intolerance (n = 7) 
Figure 1 Flow of participants.
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IRR 1.23 95% CI 1.01 to 1.50, p = 0.04). The finding
was consistent when multiple imputation was used to
account for the missing data (IRR 1.24 95% CI 1.02 to
1.50, p = 0.03).
Secondary outcomes
Secondary outcomes were the MIDAS and HIT-6, as
can be seen from Table 5. Overall there was no signifi-
cant difference between the true and sham diet groups
in terms of disability as measured by the MIDAS or
i m p a c to nd a i l yl i f ea sm e a s u r e db yt h eH I T - 6 .T h e
findings remained the same when multiple imputation
was used to account for the missing data.
Discussion
The use of the ELISA test to identify raised levels of IgG
antibodies against tested foods with subsequent diet
elimination advice reduced the number of migraines or
migraine like headaches by 23% over 4 weeks. For our
primary outcome measure, the results indicated a small
decrease in the number of migraines or migraine like
headaches over 12 weeks, although this difference was
not statistically significant. We found little or no evi-
dence that use of the ELISA test with subsequent diet
elimination advice reduced the disability or impact on
daily life as measured by the MIDAS and HIT-6
questionnaires.
Strengths and weaknesses
We believe that this is the largest randomised controlled
trial to investigate the use of diet elimination based on
the presence of IgG antibodies for the prevention of
migraine or migraine like headache. The use of ELISA
testing has been investigated for IBS [18] and more
recently for migraines [27]. One of the criticisms of the
IBS trial was that the food eliminated from the sham
diet did not appear to be as difficult as the true diet. In
this study we tried to address this criticism and we feel
that the comparability of the two diets was achieved. A
potential weakness of the current trial, was that attrition
Table 2 Participant characteristics, reported symptoms and consulting health professionals
Characteristic Sham diet
(n = 83)
True diet
(n = 84)
Total
(n = 167)
Gender (females) 72 (87%) 75 (89%) 147 (88%)
Age (years), mean (sd) 47.1 (10.1) 48.3 (11.0) 47.7 (10.6)
No. migraines past 4 weeks,
median (IQR)
5.0
(4.0 to 8.0)
6.0
(3.0 to 10.0)
6.0
(3.0 to 9.0)
Regular medication use 65 (79%) 67 (80%) 132(80%)
Symptoms experienced
Intense throbbing headache 80 (96%) 80 (95%) 160 (96%)
Increased sensitivity to light 70 (84%) 72 (86%) 142 (85%)
Nausea 63 (76%) 69 (82%) 132 (79%)
Increased sensitivity to sounds 55 (66%) 53 (63%) 108 (65%)
Increased sensitivity to smells 42 (51%) 45 (54%) 87 (52%)
Visual disturbance 44 (53%) 43 (51%) 87 (52%)
Diarrhoea 21 (25%) 17 (20%) 38 (23%)
Other 34 (41%) 43 (51%) 77 (46%)
Consulted healthcare professional
a 83 (100%) 84(100%) 167(100%)
GP 82 (99%) 84 (100%) 166 (99%)
Hospital specialists 46 (55%) 42 (50%) 88 (53%)
Headache clinic 28 (34%) 26 (31%) 54 (32%)
CAM 49 (59%) 41(49%) 90 (54%)
Other 45 (54%) 32 (38%) 77 (46%)
Consulted GP in last 3 months
Baseline (N = 167) 32 (39%) 37 (44%) 69 (41%)
3 months (N = 139) 20 (28%) 15 (22%) 35 (25%)
a This refers to any consultation
Table 3 Frequency of foods
Food Groups Sham diet True diet
Grains 34 (41%) 40 (48%)
Dairy 72 (87%) 71 (85%)
Meats 28 (34%) 20 (24%)
Fish 6 (7%) 16 (19%)
Vegetables 27 (33%) 27 (32%)
Fruits 16 (19%) 23 (27%)
Nuts 47 (57%) 46 (55%)
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weeks n = 138, 17%). Another potential weakness of the
study is that we recruited participants who self-reported
their migraines. Hence, it is possible that they were not
suffering from migraines but other forms of headache,
which would not be amenable to dietary manipulation.
Furthermore, some participants suffering from migraine
or migraine like headache in our trial will not have been
amenable to dietary manipulation as they will have suf-
fered other ‘triggers’ for their migraines or headaches.
The previous trial of diet elimination based in IgG test-
ing for migraine [27] found a difference of 2.73 days at
6 weeks whilst we found a difference of 1 day at 4
weeks. The smaller effect in our study may have been
explained by the fact our trial was more pragmatic and
we did not provide dietary support for participants and
w em a yh a v ei n c l u d e ds o m ei nt h es t u d yw h od i dn o t
have ‘true’ migraines. Furthermore, because of low
adherence with some participants not keeping to the
recommended diet this would dilute any treatment
effect. Nevertheless, despite this our findings do support
this earlier trial.
Although food intolerance has been identified in the
literature as a precipitating factor for migraine, it is
o n eo fm a n yf a c t o r sa n dt h eo n s e to fam i g r a i n em a y
be triggered by either the intolerant food(s) or the
combination of precipitating factors. However, other
factors such as menstrual status, body mass index or
ethnicity will have been balanced across by our use of
randomisation. Vaughan [8] highlights few migraine
patients can become headache free by dietary manipu-
lation alone, therefore other precipitating factors need
to be identified in order for them to be managed effec-
tively [28]. In addition, for patients to experience any
benefit from removing intolerant foods from their diet
they obviously need to adhere to the diet change. The
issue of adherence is further complicated by how
aware a patient is of the use of their excluded food(s)
in processed foods or when dining out. For example,
mayonnaise may contain egg yolks, mustard, cornflour/
maize starch, all three ingredients are possible foods
that a patient could be asked to eliminate from their
diet. To adhere to the diet a patient would need to
read all food labels carefully to identify if the food con-
tains any of their intolerant foods or ask at each dining
establishment they ate at.
Within the current study only 52% of the participants in
the true diet group returned their daily food diary. Whilst
adherence was high among this group we do not know
what it was like among the non-responders. Consequently,
we were unable to assess the impact of adherence with the
diet within the present study. Future research in this area
needs to ensure that participants adherence with the diet-
ary intervention is measured using a different tool rather
than collecting this information through daily food diaries.
Participants had to ‘self-test’ which is how this test is used
in a real life. We could not be completely sure that sam-
ples related to the participant. However, it would seem
unlikely that many, if any, participants would send another
person’s sample back.
Within the current study, all of the participants were
informed that they would be given their true test results
at 12 weeks, which may have led some participants, with
more challenging diets, to wait until they knew their
Table 4 Number of headache days
Time point Summary Sham True IRR (95% CI)* P-value
12 weeks** N
Median (IQR)
69
20 (12 to 29)
69
19 (8 to 28)
1.15 (0.94 to 1.41)
1.17 (0.96 to 1.42)
0.18
0.11
4 weeks N
Median (IQR)
78
8 (5 to 12)
78
7 (4 to 10)
1.23 (1.01 to 1.50)
1.24 (1.02 to 1.50)
0.04
0.03
*Values in italics are the results from using multiple imputation to account for the missing data
**Primary outcome
Table 5 Secondary outcomes
Outcome Summary Sham True IRR (95% CI)* P-value
MIDAS N
Median (IQR)
61
14 (6 to 24)
54
12 (5 to 23)
1.22 (0.86 to 1.73)
1.16 (0.89 to 1.51)
0.27
0.26
Outcome Summary Sham True Estimate (95% CI)* P-value
HIT6 N, 4 weeks
Mean (sd)
77
59.6 (7.8)
75
59.1 (9.0)
1.20 (-1.17 to 3.58)
1.25 (-1.11 to 3.60)
0.32
0.30
N, 12 weeks
Mean (sd)
71
59.0 (7.0)
64
59.8 (6.7)
-0.11 (-2.24 to 2.02)
-0.28 (-2.17 to 1.60)
0.92
0.77
*Values in italics are the results from using multiple imputation to account for the missing data
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other hand, our participants were all volunteers so may
be more highly motivated than the ‘average’ headache
patient.
Conclusion
In conclusion, use of the ELISA test with subsequent
diet elimination advice did not reduce the disability or
impact on daily life of migraines or migraine like head-
ache or the number of migraines or migraine like head-
ache at 12 weeks but it did significantly reduce the
number of migraines or migraine like headache at 4
w e e k s .I tm i g h tb et h a tt h ea v o i d i n gt h eu s eo fas h a m
may improve compliance as participants will know that
they are allocated to a true diet and respond better to
dietary advice.
Future trials in this area need to build in additional
nutritional support for participants to aid adherence and
n e e dt oi d e n t i f yas u i t a b l et o o lt om e a s u r ea d h e r e n c e
with the dietary intervention.
Ethical approval
The study was approved by the Research Governance
Committee in the Department of Health Sciences, Uni-
versity of York, York, UK. Written informed consent
was given by all participants.
Abbreviations
AU: arbitrary units; AU/ml: arbitrary units per millilitre of blood; CE:
Conformité Européenne (European Conformity); CI: Confidence interval;
ELISA: Enzyme Linked Immuno-Sorbent Assay; GP: General Practitioner; HIT:
Headache Impact Test; IBS: Irritable bowel syndrome; IgE: Immunoglobulin E;
IgG: Immunoglobulin G; IQR: inter quartile range; IRR: incident rate ratio; IVD:
in-vitro diagnostic; MIDAS: MIgraine Disability Assesment Scale; p: probability;
RCT: Randomised controlled trial; SAS: Statistical analysis software; SPSS:
Statistical Package for the Social Sciences.
Acknowledgements
The study was supported by the York Trials Unit, University of York, York, UK
and by a small grant from YorkTest Laboratories, York. YorkTest provided the
pin prick test and carried out the ELISA test at no cost to the study. YorkTest
played no part in the conception of the study, data collection, analysis, or
writing the article. Dr Gill Hart for her comments on the final draft of the
manuscript. Dr Peter Horlock for managing the testing of the samples
provided.
Author details
1York Trials Unit, Department of Health Sciences, University of York, York,
YO10 5DD, UK.
2Hull York Medical School, University of York, York, YO10
5DD, UK.
Authors’ contributions
NM designed the study, coordinated the study and drafted the manuscript.
CEH performed the statistical analyses and helped to draft the manuscript.
SJ performed the statistical analyses. MH, JA and IW helped to draft the
manuscript. DJT conceived of the study and helped to draft the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 May 2011 Accepted: 11 August 2011
Published: 11 August 2011
References
1. Linde K, Streng A, Jurgens S, Hoppe A, Brinhaus B, et al: Acupuncture for
patients with migraine: A randomized controlled trial. JAMA 2005,
293:2118-2125.
2. Damen L, Bruijn J, Koes BW, Berger MY, Passchier J, Verhagen AP:
Prophylactic treatment of migraine in children. Part 1. A systematic
review of non-pharmacological trials. Cephalalgia 2005, 26:(4):373-383.
3. Dahlöf CGH, Dodick D, Dowson AJ, Pascual J: How does almotriptan
compare with other triptans? A review of data from placebo-controlled
clinical trials. Headache 2002, 42:99-113.
4. Silberstein SD: Migraine symptoms: Results of a survey of self-reported
migraineurs. Headache 1995, 35(7):387-396.
5. Goadsby PJ: Recent advances in the diagnosis and management of
migraine. BMJ 2006, 332:25-29.
6. Solomon GD, Price KL: Burden of migraine: A review of scocioeconomic
impact. Pharmacoeconomics 1997, 11:1-10.
7. van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF:
Societal perspective on the burden of migraine in the Netherlands.
Pharmacoeconomics 1995, 7:170-179.
8. Vaughan TR: The role of food in the pathogenesis of migraine headache.
Clinical Reviews in Allergy 1994, 12:167-180.
9. Brown T: Role of diet in etiology and treatment of migraine and other
types of headache. JAMA 1921, 77:1396-1400.
10. Vaughan W: Allergic migraine. JAMA 1927, 88(18):1383-1386.
11. Kelman L: The triggers or precipitants of the acute migraine attack.
Cephalalgia 2007, 27:394-402.
12. van den Bergh V, Amery W, Wealkens J: Trigger factors in migraine.
Headache 1987, 27:191-195.
13. Downing D, Davies S: “Allergy: Conventional and alternative concepts”.A
critique of the Royal College of Physicians of London’s report. Journal of
Nutritional Medicine 1992, 3:331-349.
14. Physicans RCo: Allergy: Conventional and alternative concepts. London:
Royal College of Physicians of London; 1992.
15. Silberstein SD: Migraine - Author’s reply. The Lancet 2004, 363:1399.
16. Royal College of Physicians: Allergy: Conventional and alternative
concepts. London: Royal College of Physicians of London; 1992.
17. Radcliffe MJ: Elimination diets as a diagnostic tool. In Food Allergy and
Intolerance.. 2 edition. Edited by: Brostoff J, Challacombe SJ. London:
Elsevier; 2002:817-829.
18. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based
on IgG antibodies in irritable bowel syndrome: A randomised controlled
trial. Gut 2004, 53:1459-1464.
19. Bischoff S, Crowe S: Gastrointestinal food allergy: new insights into
pathophysiology and clinical perspectives. Gastroenterology 2005,
128:1089-1113.
20. Volpi N, Maccari F: Serum IgG responses to food antigens in the Italian
population evaluated by highly sensitive and specific ELISA test. Journal
of Immunoassay and Immunochemistry 2009, 30:51-69.
21. Awazuhara H, Kawai H, Maruchi N: Major allergens in soybean and clinical
significance of IgG4 antibodies investigated by IgE- and IgG4-
immunoblotting with sera from soybean-sensitive patients. Clinical and
Experimental Allergy: Journal of the British Society for Allergy and Clinical
Immunology 1997, 27(3):325-332.
22. el Rafei A, Peters SM, Harris N, Bellanti JA: Diagnostic value of IgG4
measurements in patients with food allergy. Annals of Allergy 1989,
62:94-99.
23. Høst A, Husby S, Gjesing B, Larsen JN, Løwenstein H: Prospective
estimation of IgG, IgG subclass and IgE antibodies to dietary proteins in
infants with cow milk allergy. Levels of antibodies to whole milk
protein, BLG and ovalbumin in relation to repeated milk challenge and
clinical course of cow milk allergy. Allergy 1992, 47(3):218-219.
24. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN: Validity
of the Migraine Disability Assessment (MIDAS) score in comparison to a
diary-based measure in a population sample of migraine sufferers. Pain
2000, 88(1):41-52.
25. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A,
Cady R, Dahlöf CGH, Dowson AJ, Tepper S: A six-item short-form survey
Mitchell et al. Nutrition Journal 2011, 10:85
http://www.nutritionj.com/content/10/1/85
Page 8 of 9for measuring headache impact: The HIT-6™. Quality of Life Research 2003,
12(8):963-974.
26. Ware JE, Bjorner JB, Kosinski M: Practical implications of item response
theory and computerized adaptive testing. A brief summary of ongoing
studies of widely used headache impact scales. Medical Care 2000, 38(9
Suppl II):73-82.
27. Alpay K, Ertas M, Orhan E, Ustay D, Lieners C, Baykan B: Diet restriction in
migraine, based on IgG against foods: A clinical double-blind,
randomised, cross-over trial. Cephalalgia 2010, 30:829-837.
28. Fukui P, Gonçalves T, Strabelli C, Lucchino N, Matos F, dos Santos J,
Zukerman E, Zukerman-Guendler V, Mercante J, Masruha M, et al: Trigger
factors in migraine patients. Arq Neuropsiquiatr 2008, 66(3-A):494-499.
doi:10.1186/1475-2891-10-85
Cite this article as: Mitchell et al.: Randomised controlled trial of food
elimination diet based on IgG antibodies for the prevention of migraine
like headaches. Nutrition Journal 2011 10:85.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mitchell et al. Nutrition Journal 2011, 10:85
http://www.nutritionj.com/content/10/1/85
Page 9 of 9